MPNs

Latest News

Assessing Risk for JAK Inhibitor Selection in Myelofibrosis
Assessing Risk for JAK Inhibitor Selection in Myelofibrosis

April 25th 2025

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

Considering Therapy in a Patient With Myelofibrosis Eligible for Transplant
Considering Therapy in a Patient With Myelofibrosis Eligible for Transplant

April 23rd 2025

Bexmarilimab Shows Promise in Tough-to-Treat HR MDS; Phase 3 Planned
Bexmarilimab Shows Promise in Tough-to-Treat HR MDS; Phase 3 Planned

April 18th 2025

Addressing Treatment Gaps in High-Risk CML in Blast Phase
Addressing Treatment Gaps in High-Risk CML in Blast Phase

April 4th 2025

FDA Grants Bexmarilimab Orphan Drug Designation for MDS
FDA Grants Bexmarilimab Orphan Drug Designation for MDS

March 5th 2025

More News